Skip to content

Transcutaneous Diaphragm Electrical Stimulation in Critically Ill Patients

Transcutaneous Diaphragm Electrical StimuLAtion in Critically Ill Patients to Prevent Diaphragm Dysfunction

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04171024
Acronym
TESLA
Enrollment
66
Registered
2019-11-20
Start date
2019-12-10
Completion date
2022-08-03
Last updated
2022-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Illness, Intensive Care Unit, Mechanical Ventilation

Keywords

Diaphragm dysfunction, Transcutaneous Electrical Stimulation, Intensive care unit, Mechanical ventilation

Brief summary

This study evaluates the effect of a transcutaneous electrical stimulation in critically ill patients compared to a sham electrical stimulation to decrease the incidence of diaphragm dysfunction before mechanical ventilation weaning.

Interventions

A non invasive sham diaphragm electrical stimulation using transcutaneous thoracic probes

DEVICETranscutaneous diaphragm electrical stimulation

A non invasive diaphragm electrical stimulation using transcutaneous thoracic probes

Sponsors

Groupe Hospitalier du Havre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Patients intubated and ventilated for at least 24 h * Patients who were expected to have at least 48h after inclusion

Exclusion criteria

* Patient with pacemaker * Patient under neuro muscular blocker * Patient post thoracic or abdominal surgery * Patient with BMI more than 35 kg/m² * Patient with degenerative neurological pathology * Patient with cutaneous lesion may be interfered with probes * Patient with chronic loss of autonomy * Patient hospitalized more than 72 hours before ICU admission * Patient with severe chronic obstructive pulmonary disease (FEV1 \< 30%) * Patient with decision to withhold life-sustaining treatment

Design outcomes

Primary

MeasureTime frameDescription
Diaphragm Thickening fractionOnce, At the start of the spontaneous breathing trialDiaphragm ultrasound was conducted using a 4-12-MHz linear array transducer. Diaphragm thickness was measured at end-expiration (Tdi,ee) and end inspiration (Tdi,ei), and thickening fraction (TFdi) was calculated offline as (Tdi,ei-Tdi,ee)/Tdi,ee.

Secondary

MeasureTime frameDescription
Diaphragm atrophyOnce a day under mechanical ventilation, throughout the studyDiaphragm thickeness is measured each day of the study until mechanical ventilation weaning
Inspiratory strengthOnce, At the start of the spontaneous breathing trialMaximal inspiratory pressure is measured via an electrical manometer with unidirectional valve
Cough strengthOnce, At the start of the spontaneous breathing trialPeak expiratory cough flow is measured with the ventilator
Proportion of patients successfully liberated from the ventilatorAfter 3 days of spontaneous breathingExtubation failure is reported when a patient present a respiratory distress and need an tracheal intubation in the 48 hours past extubation

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026